Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Why start-ups can become mega companies in the pharma sector

In a previous BioVox article, we analyzed the steps needed for a life sciences start-up to turn into a fully integrated, commercial stage biotech …


How to build a “European Amgen”

There are still very few large European biotech companies to compete with the Amgens and Gileads of the world.  Only a handful of European biotech…


Belgium vs Germany in the Life Sciences start-up championship

Germany is one of the leading industrial nations in the world and has 8x more inhabitants than Belgium. However, when it comes to investments in e…

POPULAR TAGS

Device for 3D hologram images of cells

Written by DS on in the category news with the tags , .


Ovizio, launched in 2009 as spin-off from the ULB, develops ultra specialized microscopes allowing creation of a hologram-like 3D image of biological cells. The device is ideal to follow up on the evolution of cells in laboratory research. For example, it visualizes how cancer cells work and which cells survive.

"We started from the idea of simplifying diagnosis with our microscopes," says Philip Mathuis, CEO of Ovizio. "In 2012, we build a device that gave the result of a pap smear within a few minutes.”

"However, we soon realized that producing medical devices is a difficult task. The certification brings an administrative burden," Mathuis continues. "We then decided to focus on microscopes that could be used in bioreactors. This is a clear niche, where we can grow before turning to medical diagnosis again. Bioreactors require the continuous monitoring of the growth of the cells. Our devices can do this automatically, which will reduce the costs with 60% to 70%.”

An important client of Ovizio is GSK in Rixensart. "This pharmaceutical company helped us to test and validate our microscopes and uses it now," says Mathuis. "Another deal with a pharma group would obviously help us, as they immediately might need hundreds of the devices."

Ovizio gathered eight million euros from investors to speed up the commercialization of its microscopes. Qbic, Nausicaa Ventures and Theodore III signed in, as well as Pierre Drion, the former chief executive of Petercam. Also an American investment fund will sign in, New Science Ventures, which will help to launch sales in the US. "Different partners will assist us in the distribution. Having an investor in the US, is a positive signal to the US market,” says Mathuis.

Read more about: , .

RELATED ARTICLES
Why start-ups can become mega companies in the pharma sector

In a previous BioVox article, we analyzed the steps needed for a life sciences start-up to turn into a fully integrated, commercial stage biotech …


How to build a “European Amgen”

There are still very few large European biotech companies to compete with the Amgens and Gileads of the world.  Only a handful of European biotech…


Belgium vs Germany in the Life Sciences start-up championship

Germany is one of the leading industrial nations in the world and has 8x more inhabitants than Belgium. However, when it comes to investments in e…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Itera Life Science GSK XpandInnovation Janssen Turnstone Biowin Flanders.bio UGent KU Leuven V-Bio Ventures

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.